Core Viewpoint - The company, Gilead Sciences-B (01672), is experiencing a stock price increase of over 6%, currently trading at 13.76 HKD with a transaction volume of 32.67 million HKD, following the announcement of a new share placement to raise approximately 835 million HKD for clinical trials [1] Group 1: Share Placement and Financials - Gilead Sciences plans to place 69.256 million new shares, expecting net proceeds of about 835 million HKD [1] - 90% of the net proceeds will be allocated for the preparation and initiation of global Phase III clinical trials for the oral GLP-1 receptor agonist ASC30 targeting obesity [1] - The remaining 10% will be used for working capital and general corporate purposes [1] Group 2: Clinical Trials and Research Updates - The company announced that the Phase II study (NCT07321678) of ASC30 for treating type 2 diabetes in the U.S. has completed the dosing of the first batch of participants [1] - Top-line data from this Phase II study is expected to be available in the third quarter of 2026 [1]
歌礼制药-B午后涨超6% 公司拟净筹逾8亿元用于减肥药全球临床试验